



VitalTransformation

The impact of health technology made simple

France

A New Method, New Framework, and
New Roadmap for Improved Patient Access

December 20, 2019



MSD

INVENTING FOR LIFE

Speakers

Eric Baseilhac

Director of Economic and
International Affairs
LEEM (France)

David Watson

Director of Commercial Policy
ABPI (UK)

Pedro Luis Sánchez




Director Studies Department
Farmaindustria (Spain)

Duane Schulthess

Managing Director
Vital Transformation
(moderator)

How is your connection? Ask a question?

If you are having problems with your connection, you can switch between phone and computer audio



The final 30 min of the webinar will be for audience Q&A, please use the question bar in the control panel

Question 1

There are huge disparities in the time to market access across Europe currently, over 500 days in France, 374 in Spain and roughly 100 days in Germany and the UK. What is driving these differences in time to market?

Question 1

There are huge disparities in the time to market access across Europe currently, over 500 days in France, 374 in Spain and roughly 100 days in Germany and the UK. What is driving these differences in time to market?

What is the key constraint in the access criteria that is creating such a long time-lag in France, as well as Spain? How can reforms be enacted to improve both evaluation and time?

Question 2

An increasing challenge is the emerging area in oncology of combo therapies? If we're already having difficulty with one asset, how are we going to manage access with new, novel combo therapies?

Question 3

The UK cancer drugs fund went through a radical overhaul in 2016; how is the fund performing now in bringing novel oncology treatments to patients? Does this accommodate combo-therapies in it's scope?

Question 4

What has the experience been in France with the Temporary Authorisation for Use (ATU)? Do the current proposals to accelerate patient access in France make changes to the ATU?

Question 5

Given the independent nature of the regions of Spain, do you see large differences in the time it takes to approve new medicines for reimbursement? How much collaboration is there between the regions?

Question 6

The UK four years ago put in place the Early Access to Medicines Scheme to improve patient access. Can you give us an overview of the EAM?

Last year, Paul Catchpole of the ABPI team was quoted as saying, “For EAMS to work, it requires a multi-agency response. . .The MHRA has done a great job at what needs to happen at the front-end of the process. It’s how the other agencies respond down the line that needs fixing.” How has the EAMs done since this meeting and is the EAMS process improving?

Question 7

In November 2018 the ABPI and UK government agreed for faster access in exchange for 2% spending cap on branded medicines, how is that agreement working in practice?

Question 8

Last year, the European Commission and EUnetHTA were trying to establish a unified HTA process. Sadly, that seems to have not gotten beyond the discussion stage. Given the divergent times to market we see between EU countries, would a unified HTA process help?

Question 9

We understand that the French reform measures related to the evaluations of new medicines have not yet been approved. What are the next steps to try to progress the legislation?



Question 10

How is the UK government adapting to Brexit from the standpoint of HTA and Reimbursement? Given challenges of EU policies such as the hospital exemption, do you think Brexit will create both challenges and opportunities for biopharma research in areas such as CRISPR and CAR-T?

Audience Questions

Eric Baseilhac

Director of Economic and
International Affairs
LEEM (France)



David Watson

Director of Commercial Policy
ABPI (UK)

Duane Schulthess

Managing Director
Vital Transformation
(moderator)

Final Question

Looking ahead 5 years for each of you, what changes do you see being made in your respective government processes to improve patient access?



VitalTransformation

The impact of health technology made simple

Thank You!

France

A New Method, New Framework, and
New Roadmap for Improved Patient Access

December 20, 2019



MSD

INVENTING FOR LIFE